Thursday 16 October, 2025
Introduction: Health economic decisions rely on the evaluation of complex systems. The complexity demonstrates itself in several aspects: (1) each…
Read morePoster: Methodology - New Modelling Approaches
Crossing borders from mechanistic QSP to clinical population modeling
Thursday 16 October, 2025
Introduction: The field of pharmacometrics had decades to evolve and establish itself as an indispensable component of drug development in…
Read moreA novel approach to estimate ontogenies for PBPK applications – From literature data to simulations
Thursday 16 October, 2025
Objectives: Application of physiologically based pharmacokinetic (PBPK) modelling in pediatric and geriatric populations requires a detailed understanding of age-dependent physiological…
Read moreBayesian individual dynamic predictions of biomarkers and risk of event in joint modelling (with uncertainty): a comparison between Stan, Monolix and NONMEM
Thursday 16 October, 2025
Objectives: Joint models of drug or biomarker kinetics and occurrence of event are increasingly used in drug development using nonlinear…
Read morePositive allosteric modulators – a challenge for development of QSP models
Thursday 16 October, 2025
Background: Positive allosteric modulator (PAM)-antagonists exhibit paradoxical pharmacological profiles by simultaneously increasing agonist affinity whilst decreasing the efficacy of the agonist…
Read moreQSP Modelling of Neurodegenerative Chronic Diseases and Brain Biomarkers: Adding the Effect of Ageing on Brain Volume
Thursday 16 October, 2025
Introduction: Physiological modelling and simulation including brain physiology (and/or pharmacology) have been typically based on the assumption that brain is…
Read moreComparison of Phase I combination therapy designs by clinical trial simulations to evaluate early tumor shrinkage
Thursday 16 October, 2025
Objectives: In oncology, there is a growing interest in the use of combination therapies in early clinical trials, but most…
Read moreSystems pharmacology modelling of the alternative pathway to study target suitability
Thursday 16 October, 2025
Objectives: The complement system (CS) is an integral part of the innate immune system. Its effector functions include pathogen clearance…
Read moreAn open source software solution for automating pharmacokinetic/pharmacodynamic model selection
Thursday 16 October, 2025
Objectives:The current approach to population PKPD model selection is formally known as downhill search and is a local search method….
Read moreShared Learning from a Physiologically-Based Pharmacokinetic Modeling Strategy for Human Pharmacokinetics Prediction through Retrospective Analysis of Genentech Compounds
Thursday 16 October, 2025
Introduction: Quantitative prediction of human pharmacokinetics (PK) including the PK profile and key PK parameters are critical for early drug…
Read more